Zaloguj Zarejestruj się zadarmo

Accelerate Diagnostics Inc organizacji Cena/Sprzedaż

Jaka jest wartość Cena/Sprzedaż organizacji Accelerate Diagnostics Inc?

Wartość Cena/Sprzedaż organizacji Accelerate Diagnostics Inc to 3.70

Jaka jest definicja Cena/Sprzedaż?



Wskaźnik ceny do zysku (Price to sales ratio) to wskaźnik reprezentuje koszt firmy w porównaniu do kwoty jej sprzedaży.

The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.

A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.

Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.

Cena/Sprzedaż firm w Health Care sektor na NASDAQ w porównaniu do Accelerate Diagnostics Inc

Czym się zajmuję organizacja Accelerate Diagnostics Inc?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Firmy z cena/sprzedaż podobne do Accelerate Diagnostics Inc